Osimertinib has been nothing short of a game-changer for a segment of lung cancer sufferers. For the approximately 30% of patients with non-squamous non-small cell lung cancer (NSCLC) who carry an EGFR mutation, osimertinib has stretched out the average expected survival from months to years. To date, osimertinib has only been studied as a single agent. Until now…..

At the ESMO Annual Congress in 2022, study author Dr Camillo Porta provided an update on the study results in all IMDC risk groups, with a median follow-up of 33.7 months…

In an article published in JAMA Oncology in February 2023, Cella et al. have published validation of a new risk prediction model with the ONKOTEV-2 study for outpatients with cancer.